RenalEndocrinology
Diabetic Nephropathy
Annual albuminuria screen, RAAS blockade, SGLT2i + finerenone, glycaemic + BP optimisation, plan for renal replacement.
Source: KDIGO 2022 Diabetes; NICE NG28; ADA 2024
Step 1 of ~5
info
Recognise + Stage
Annual screening from diagnosis (T2DM) and from 5y post-diagnosis (T1DM): urine ACR (early-morning, repeat if abnormal); eGFR. Stage CKD by eGFR + albuminuria (KDIGO heat map). Differentiate from non-diabetic kidney disease: rapid decline, haematuria, low complement, atypical features, age <10y diabetes — biopsy.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Finerenone · Non-Steroidal Mineralocorticoid Receptor Antagonist (Diabetic CKD)
- Atrasentan · Selective Endothelin-A Receptor Antagonist (Diabetic Nephropathy)
- Sugammadex · Selective Neuromuscular Blockade Reversal Agent
- Sodium chloride · Saline IV fluid / replacement
- Hydrocortisone (Oral Replacement) · Glucocorticoid Replacement
- Testosterone (Replacement) · Androgen (Male Sex Hormone)
Pathways
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019
Decision support only. Always apply local guidelines and clinical judgement.